Rebiscan
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Rebiscan sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Rebiscan: 9 sponsored US clinical trials, 1 recruiting.
Rebiscan sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. The most-studied condition in this pipeline is Brain Injuries, Traumatic, with 3 trials.
Top-decile sponsor footprint
Rebiscan ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
mTBI Identification and Monitoring Through Retinal Scanning
NCT06142435
Head and Intraocular Trauma Tool for the Identification of Mild Traumatic Brain Injury
NCT05092295
HITT for the Identification of Mild Traumatic Brain Injury
NCT05092282
Neuro-ocular Baselines in a Sports Setting
NCT03653936
HITT Device Pilot Testing for Traumatic Brain Injury
NCT03249818
Improving Quality Vision Outcomes in Managed Care Setting While Reducing Cost by Use of Accurate, Automated Screening
NCT02536963
Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
NCT01706991
Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
NCT01832883
Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
NCT01726842
Therapeutic Areas
What is open in the Rebiscan pipeline
1 recruiting of 9 indexed (11% open); 6 completed (67%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Brain Injuries, Traumatic (3 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rebiscan: open-pipeline peers nationwide
Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Rebiscan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this Rebiscan page
9 registered trials is a research-attention snapshot, not an endorsement of Rebiscan or any single study.
- 1 of Rebiscan's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Brain Injuries, Traumatic is the condition Rebiscan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Brain Injuries, Traumatic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rebiscan pipeline card: 9 registered trials from official public datasets.Report a data error.